The Association of Breast Surgery (ABS), National Coordinating Committee for Breast Pathology (NCCBP), and Royal College of Radiology (RCP) have issued guidelines regarding the management of patients newly diagnosed with breast cancer during COVID-19 pandemic.

Alteration of standard management of patients with breast symptoms and breast cancer have occured in many parts of the UK due to redirection of healthcare provisions to patients suffering with COVID-19. These potential alterations in treatment should be monitored and studied in an observational cohort study. 

If your hospital provides breast cancer treatment in the UK and Republic of Ireland, please register for this study study 

We hope to gather important (anonymised) data about patients who may be affected by the COVID19 pandemic in the following categories: 

Pre-operative:

Operative:

Post-operative:

  • Altered pre-operative imaging assessment (including biopsy) 
  • Omitted / Incomplete neoadjuvant chemotherapy
  • ‘Bridging’ endocrine therapy prior to delayed surgery
  • Neo-adjuvant radiotherapy 
  • Delay in surgery (>31 days from diagnosis) 
  • Breast conserving surgery with NO/UNKNOWN planned radiotherapy 
  • Simple mastectomy performed, when breast conservation followed by adjuvant radiotherapy would have been indicated
  • Simple mastectomy performed, with a view to delayed reconstruction, when immediate reconstruction  would have been offered
  • Patient not having (otherwise indicated) margin re-excision surgery or completion axillary clearance 
  • No sentinel node biopsy for incidental invasion (found during surgery for DCIS)
  • No adjuvant radiotherapy
  • ‘Altered’ radiotherapy, with 5 fractions (early adoption of FAST and FASTforward protocol)
  • No adjuvant chemotherapy
  • No adjuvant targeted anti-HER2 (e.g. herceptin) therapy 
  • Use of Genomic testing (e.g. ONCOTYPE) used outside of NICE guidelines (2018)